![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Mirtazapine, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2008-205 - Rev 05
This Chemical Type CEP, issued on April 06, 2022, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2338 associated with this CEP further emphasizes